ArticleJournal of pharmaceutical policy and practice2026
Economic burden of Generalized Pustular Psoriasis in Malaysia: a multi-centre analysis of indirect costs.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Generalized Pustular Psoriasis (GPP) constitutes a rare yet severe variant of psoriasis, characterised by extensive pustule formation on the skin and imposes a significant economic burden. The study aimed to investigate the indirect costs associated with GPP in Malaysia, encompassing patients' work productivity losses and out-of-pocket expenses. Methods: This primary, multicentre, cross-sectional cost analysis study was conducted among patients diagnosed with GPP attending public hospitals under the Ministry of Health (MOH) in Malaysia. The indirect costs were assessed using the Work Productivity and Activity Impairment (WPAI) tool and standardised data collection form. Data were statistically analysed using descriptive and inferential statistics using IBM SPSS version 28.0. Results: A total of 54 patients with GPP were enrolled in the study, with about one-fourth experiencing flares at the time of the interview. The total annual indirect cost associated with GPP was estimated at MYR 676,081 (MYR 12,520 per patient). The indirect costs of GPP were driven largely by work productivity loss. Both work and activity impairment were significantly higher during GPP flare periods compared to non-flare periods. Additionally, the annual work impairment cost per patient was substantially higher during GPP flare periods, indicating a marked increase in economic burden compared with the non-flare group. Conclusion: The study demonstrates a substantial indirect economic burden of GPP, driven primarily by work productivity loss, particularly during acute flares. These findings highlight the broader socioeconomic impact of GPP beyond direct costs. Strategies to enhance patients' presenteeism, reduce absenteeism, and prevent unemployment are likely to have the greatest impact on reducing societal costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.